Literature DB >> 22570188

Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery.

Laura T Pizzi1, Richard Toner, Kathleen Foley, Erin Thomson, Wing Chow, Myoung Kim, Joseph Couto, Marc Royo, Eugene Viscusi.   

Abstract

STUDY
OBJECTIVE: To determine whether there is an association between opioid-related adverse effects and postoperative hospital length of stay (p-LOS).
DESIGN: Retrospective medical record review.
SETTING: Large academic medical center. PATIENTS: Random sample of 402 patients (mean age 60.2 yrs, 50.3% female) who underwent orthopedic spine, hip, knee, or shoulder surgery during 2007 and received opioids during or after the procedure.
MEASUREMENTS AND MAIN RESULTS: Potential opioid-related adverse effects were identified by using established criteria. Bivariate and multivariate analyses (generalized linear regression model, log transformed) were used to identify predictors of p-LOS. The model also estimated the effect of specific types of adverse effects and adverse-effect combinations on p-LOS. Mean ± SD p-LOS was 3.0 ± 2.1 days; median oral morphine equivalent postoperative dose was 60 mg/day. More than half of the patients (54.2%) experienced one or more adverse effects, 25.6% experienced two or more adverse effects, and 7.2% experienced three or more adverse effects. The composite of nausea and vomiting was experienced by 36.1% of study patients, and 12.6% had at least one emesis episode. Constipation and confusion were documented in 6.5% and 3.7% of patients, respectively. Constipation (p<0.0001), emesis (p<0.001), and confusion (p<0.01) were associated with increased p-LOS after adjusting for other significant variables. Patients with constipation had an adjusted 49% (95% confidence interval [CI] 25-77%) longer p-LOS (additional 1.4 days) compared with patients without constipation. Emesis and confusion significantly increased p-LOS by 25% (95% CI 10-42%) and 38% (95% CI 11-72%), respectively. Incremental increases in p-LOS for patients with two adverse effects (p=0.02), three adverse effects (p<0.001), and four adverse effects (p<0.001) versus patients with no adverse effects were 15%, 40%, and 82%, respectively.
CONCLUSION: Constipation, emesis, and confusion were associated with increased p-LOS in patients receiving opioids after orthopedic surgery. In addition, there was a significant linear relationship between the number of adverse effects/patient and increased p-LOS, and the strength of the association increased as the number of adverse effects increased. Although the opioid dosages and adverse-effect rates were typical, these findings reinforce the need to balance pain management with risk of events.
© 2012 Pharmacotherapy Publications, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22570188     DOI: 10.1002/j.1875-9114.2012.01101.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  30 in total

Review 1.  Systemic Complications and Radiographic Findings of Opioid Use and Misuse: An Overview for Orthopedic Surgeons.

Authors:  Harry G Greditzer; Dustin H Massel; Carlos M Barrera; Nisreen S Ezuddin; Christopher P Emerson; Jean Jose
Journal:  HSS J       Date:  2018-12-07

2.  A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Acetaminophen on Hospital Length of Stay in Obese Individuals Undergoing Sleeve Gastrectomy.

Authors:  Farrell E Cooke; Jon D Samuels; Alfons Pomp; Farida Gadalla; Xian Wu; Cheguevara Afaneh; Gregory F Dakin; Peter A Goldstein
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

3.  Intravenous Acetaminophen Reduces Length of Stay Via Mediation of Postoperative Opioid Consumption After Posterior Spinal Fusion in a Pediatric Cohort.

Authors:  Vanessa A Olbrecht; Lili Ding; Kristie Spruance; Monir Hossain; Senthilkumar Sadhasivam; Vidya Chidambaran
Journal:  Clin J Pain       Date:  2018-07       Impact factor: 3.442

Review 4.  Effectiveness of interventions on the appropriate use of opioids for noncancer pain among hospital inpatients: A systematic review.

Authors:  Shania Liu; Danijela Gnjidic; Jessica Nguyen; Jonathan Penm
Journal:  Br J Clin Pharmacol       Date:  2020-01-17       Impact factor: 4.335

5.  Risk Factors for Severe Opioid-Related Adverse Events in a National Cohort of Medical Hospitalizations.

Authors:  Shoshana J Herzig; Mihaela S Stefan; Penelope S Pekow; Meng-Shiou Shieh; William Soares; Karthik Raghunathan; Peter K Lindenauer
Journal:  J Gen Intern Med       Date:  2019-11-14       Impact factor: 5.128

Review 6.  Inappropriate opioid prescription after surgery.

Authors:  Mark D Neuman; Brian T Bateman; Hannah Wunsch
Journal:  Lancet       Date:  2019-04-13       Impact factor: 79.321

7.  Efficacy of direct arthroscopy-guided suprascapular nerve block after arthroscopic rotator cuff repair: a prospective randomized study.

Authors:  Jae Jun Lee; Yon-Sik Yoo; Jung-Taek Hwang; Do-Young Kim; Seong-Jae Jeon; Sung Mi Hwang; Ji Su Jang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-03-01       Impact factor: 4.342

8.  Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR.

Authors:  Andrew Paris; Chris M Kozma; Wing Chow; Anisha M Patel; Samir H Mody; Myoung S Kim
Journal:  Am Health Drug Benefits       Date:  2013-11

9.  Cost-effectiveness of intravenous acetaminophen and ketorolac in adolescents undergoing idiopathic scoliosis surgery.

Authors:  Vidya Chidambaran; Rajeev Subramanyam; Lili Ding; Senthilkumar Sadhasivam; Kristie Geisler; Bobbie Stubbeman; Peter Sturm; Viral Jain; Mark H Eckman
Journal:  Paediatr Anaesth       Date:  2018-01-29       Impact factor: 2.556

10.  Evaluating the affect and reversibility of opioid-induced androgen deficiency in an orthopaedic animal fracture model.

Authors:  Jesse Chrastil; Christopher Sampson; Kevin B Jones; Thomas F Higgins
Journal:  Clin Orthop Relat Res       Date:  2014-02-19       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.